Immunohistochemical expression of proinflammatory cytokines IL-1β, IL-6, TNF-α and involvement of COX-2, quantitatively confirmed by Western blot analysis, in Wernicke's encephalopathy

Pathology Research and Practice

Volumn 207, Issue 10, 2011, Pages 652-658

  Neri, Margherita ^a   Cantatore, Santina ^a   Pomara, Cristoforo ^a   Riezzo, Irene ^a   Bello, Stefania ^a   Turillazzi, Emanuela ^a   Fineschi, Vittorio ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

COX 2; IL 1 ; IL 6; Immunohistochemistry; TNF ; Wernicke's encephalopathy; Western blot

Indexed keywords

CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BRAIN REGION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFOCAL MICROSCOPY; CYTOKINE PRODUCTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LENGTH OF STAY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; WERNICKE ENCEPHALOPATHY; WESTERN BLOTTING;

ADULT; BLOTTING, WESTERN; CYCLOOXYGENASE 2; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FATAL OUTCOME; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; PARENTERAL NUTRITION, TOTAL; POSTOPERATIVE COMPLICATIONS; TUMOR NECROSIS FACTOR-ALPHA; WERNICKE ENCEPHALOPATHY;

EID: 80755190120     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2011.07.005     Document Type: Article

References (30)

1. Bradford M.M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
2. Desjardins P., Butterworth R.F. Role of mitochondrial dysfunction and oxidative stress in the pathogenesis of selective neuronal loss in Wernicke's encephalopathy. Mol. Neurobiol. 2005, 31:17-25.
3. Donnino M.W., Vega J., Miller J., Walsh M. Myths and misconceptions of Wernicke's encephalopathy: what every emergency physician should know. Ann. Emerg. Med. 2007, 50:715-721.
4. Drachman D.B., Rothstein J.D. Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann. Neurol. 2000, 48:792-795.
5. Gibson G.E., Ksiezak-Reding H., Sheu K.F.R., Mykytyn V., Blass J.P. Correlation of enzymatic, metabolic and behavioral deficits in thiamine deficiency and its reversal. Neurochem. Res. 1984, 9:803-814.
6. Gu B., Desjardins P., Butterworth R.F. Selective increase of neuronal cyclooxygenase-2 (COX-2) expression in vulnerable brain regions of rats with experimental Wernicke's encephalopathy: effect of nimesulide. Metab. Brain Dis. 2008, 23:175-187.
7. Hakim A.M., Pappius H.M. Sequence of metabolic, clinical, and histological events in experimental thiamine deficiency. Ann. Neurol. 1983, 13:365-375.
8. Hakim A.M. Effect of thiamine deficiency and its reversal on cerebral blood flow in the rat. Observations on the phenomena of hyperperfusion, " no reflow" , and delayed hypoperfusion. J. Cereb. Blood Flow Metab. 1986, 6:79-85.
9. Harper C.G., Giles M., Finlay-Jones R. Clinical signs in the Wernicke-Korsakoff complex: a retrospective analysis of 131 cases diagnosed at necropsy. J. Neurol. Neurosurg. Psychiatry 1986, 49:341-345.
10. Hazell A.S., Wang C. Downregulation of complexin I and complexin II in the medial thalamus is blocked by N-acetylcysteine in experimental Wernicke's encephalopathy. J. Neurosci. Res. 2005, 79:200-207.
11. Hazell A.S. Astrocytes are a major target in thiamine deficiency and Wernicke's encephalopathy. Neurochem. Int. 2009, 55:129-135.
12. Hazell A.S., Butterworth R.F. Update of cell damage mechanisms in thiamine deficiency: focus on oxidative stress, excitotoxicity and inflammation. Alcohol Alcohol. 2009, 44:141-147.
13. Héroux M., Butterworth R.F. Reversible alterations of cerebral x-aminobutyric acid in pyrithiamine-treated rats: implications for the cerebral pathogenesis of Wernicke's encephalopathy. J. Neurochem. 1988, 51:1221-1226.
14. Hoffmann C. COX-2 in brain and spinal cord implications for therapeutic use. Curr. Med. Chem. 2000, 7:1113-1120.
15. Karuppagounder S.S., Shi Q., Xu H., Gibson G.E. Changes in inflammatory processes associated with selective vulnerability following mild impairment of oxidative metabolism. Neurobiol. Dis. 2007, 26:353-362.
16. Kaufmann W.E., Worley P.F., Pegg J., Bremer M., Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:2317-2321.
17. Marcheselli V.L., Bazan N.G. Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. Inhibition by a platelet-activating factor antagonist. J. Biol. Chem. 1996, 27:24794-24799.
18. Matsushima K., MacManus J.P., Hakim A.M. Apoptosis is restricted to the thalamus in thiamine-deficient rats. Neuroreport 1997, 8:867-870.
19. McRee R.C., Terry-Ferguson M., Langlais P.J., Chen Y., Nalwalk J.W., Blumenstock F.A., Hough L.B. Increased histamine release and granulocytes within the thalamus of a rat model of Wernicke's encephalopathy. Brain Res. 2000, 858:227-236.
20. Meng J.S., Okeda R. Neuropathological study of the role of mast cells and histamine-positive neurons in selective vulnerability of the thalamus and inferior colliculus in thiamine-deficient encephalopathy. Neuropathology 2003, 23:25-35.
21. 13C nuclear magnetic resonance spectroscopy. J. Neurosci. Res. 2005, 79:33-41.
22. Pasinetti G.M., Aisen P.S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998, 87:319-324.
23. Pepicelli O., Fedele E., Bonanno G., Raiteri M., Ajmone-Cat M.A., Greco A., Levi G., Minghetti L. In vivo activation of N-methyl-D-aspartate receptors in the rat hippocampus increases prostaglandin E2 extracellular levels and triggers lipid peroxidation through cyclooxygenase-mediated mechanisms. J. Neurochem. 2002, 81:1028-1034.
24. Riezzo I., Cerretani D., Fiore C., Bello S., Centini F., D'Errico S., Fiaschi A.I., Giorgi G., Neri M., Pomara C., Turillazzi E., Fineschi V. Enzymatic-nonenzymatic cellular antioxidant defense systems response and immunohistochemical detection of MDMA, VMAT2, HSP70, and apoptosis as biomarkers for MDMA (Ecstasy) neurotoxicity. J. Neurosci. Res. 2010, 88:905-916.
25. Sankarapandi S., Zweier J.L., Mukherjee G., Quinn M.T., Huso D.L. Measurement and characterization of superoxide generation in microglial cells: evidence for an NADPH oxidase-dependent pathway. Arch. Biochem. Biophys. 1998, 353:312-321.
26. Sechi G.P., Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007, 6:442-455.
27. Todd K.G., Butterworth R.F. Early microglial response in experimental thiamine deficiency: an immunohistochemical analysis. Glia 1999, 25:190-198.
28. Van Wagoner N.J., Benveniste E.N. Interleukin-6 expression and regulation in astrocytes. J. Neuroimmunol. 1999, 100:124-139.
29. Vemuganti R., Kalluri H., Yi J.H., Bowen K.K., Hazell A.S. Gene expression changes in thalamus and inferior colliculus associated with inflammation, cellular stress, metabolism, and structural damage in thiamine deficiency. Eur. J. Neurosci. 2006, 23:1172-1188.
30. Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., Worley P.F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993, 11:371-386.